NFL Study Confirms Safety & Tolerability of Treatment in Sporadic ALS & SOD1 Mutation Patients
AL-S Pharma AG Advances ALS Trial, Reports Safety in Sporadic and SOD1 Mutation Patients AL-S Pharma AG, a Swiss biotechnology company, has announced preliminary results from a Phase 1 clinical trial evaluating its experimental therapy for amyotrophic lateral sclerosis (ALS), according to a statement released on October 15, 2023. The trial, conducted across multiple European … Read more